Pharmaceutical Researcher and Manufacturers of America

What Pharmaceutical Researcher and Manufacturers of America does

PhRMA is a US-based non-profit trade association founded in 1958 that represents the country's leading pharmaceutical research and biopharmaceutical manufacturers, including Pfizer, Eli Lilly, AstraZeneca, Bristol Myers Squibb, Novartis, Janssen, Boehringer Ingelheim, Novo Nordisk, Gilead, and Regeneron. Headquartered in Washington D.C. with 251–500 employees, it functions as a policy advocacy organization rather than a product vendor; its central activities are federal and state lobbying, legal action, advertising campaigns, public testimony, and industry coordination on drug pricing, intellectual property, tariffs, and FDA regulation. Its core "deliverable" is representation—mobilizing collective industry influence in Washington against policies the membership judges harmful, such as Medicare drug price negotiation, Most-Favored-Nation pricing, Section 232 pharmaceutical tariffs, and 340B program reforms.

The association is funded by member company dues and deploys those resources primarily into political and policy influence. PhRMA spent a record $38 million on lobbying in 2025 and $12.2 million in Q1 2026 alone, including campaigns pushing the EPIC Act, opposing Most-Favored-Nation pricing, opposing Section 232 pharmaceutical tariffs, and targeting the 340B drug discount program via a seven-figure ad campaign. It has also engaged internationally, including 2026 discussions with China's Ministry of Commerce alongside five major multinational pharma firms on investment conditions and IP protections, and lent industry support to US Section 301 tariff action against Germany.

Membership is the core distribution and revenue mechanism: dues from member companies fund operations, and strategic priorities are coordinated across the membership base. The organization lost three members (AbbVie, AstraZeneca, Teva) in 2023 following passage of the Inflation Reduction Act, representing both a retention risk and a signal of the political pressures the industry faces. CEO Stephen Ubl announced his departure effective end of 2026 after more than a decade leading the organization—the longest tenure in PhRMA's 68-year history—with a board-led succession search now underway.

Name

Pharmaceutical Researcher and Manufacturers of America

Legal name

Pharmaceutical Research and Manufacturers of America

Website

https://phrma.org

Company type

Private

Founded year

1958

Operating status

Operating

Headcount range

251–500 employees

Short description

PhRMA is a Washington, D.C.-based non-profit trade association founded in 1958 that represents leading US pharmaceutical research and biopharmaceutical manufacturers, operating as the industry's primary lobbying and policy advocacy organization on drug pricing, IP, tariffs, and FDA regulation.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Advocacy

akta.pro primary industry

Healthcare & Life Sciences PR (MPAAADAD)

akta.pro secondary industry

Policy, Regulatory & Public Affairs Research (BPAHALAF)

Keywords

• Pharmaceutical trade association
• Drug pricing advocacy
• Industry policy lobbying
• Pharmaceutical research representation
• Biopharmaceutical industry advocacy

Headquarters

HQ city

Washington

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Marketing or Sales, Personnel, Operations

Distribution channels1 record

Marketing channels4 records

Core offering

PhRMA is a nonprofit trade association that represents pharmaceutical research and biopharmaceutical companies in the United States. It advocates on behalf of its member companies on legislative, regulatory, and policy matters, with a particular focus on drug pricing, intellectual property protection, FDA regulation, and trade policy. The organization conducts lobbying, public advocacy campaigns, and policy research to influence healthcare legislation and regulation.

Product overview

PhRMA is a trade association representing pharmaceutical research and biotechnology companies in the United States. It does not offer products or services in the traditional sense; rather, it serves as an advocacy organization that represents its member companies on policy, regulatory, and legislative matters related to drug pricing, FDA regulation, trade policy, and healthcare policy. The association engages in lobbying, public advocacy, and policy research on behalf of the pharmaceutical industry.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Record $38 million lobbying spend in 2025 to influence drug pricing legislation
• +1 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• China's Ministry of Commerce (MOFCOM)coreStrategic or Co-development Partner · 22 March 2026PhRMA participated in discussions with China's Commerce Minister Wang Wentao and executives from five global pharmaceutical companies (Novartis, AstraZeneca, Roche Group, Boehringer Ingelheim, and Organon) as part of China's push to reverse declining foreign investment. Wang highlighted China's five-year economic plan identifying biotechnology and pharmaceuticals as a cornerstone industry and promised enhanced intellectual property protections.
• Five Major Multinational Pharmaceutical CompaniescoreOthersChina's Commerce Minister Wang Wentao met with executives from five major multinational pharmaceutical companies and the head of US trade group PhRMA to discuss the business environment for foreign pharma firms in China. The talks focused on investment incentives, intellectual property protection, and China's support for biopharmaceuticals as a priority industry.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• U.S. Chamber of Commerce: The US Chamber is the largest US business trade association and a frequent coalition partner with PhRMA on tax, trade, IP, and litigation issues — comparable in scale of federal advocacy infrastructure and annual disclosure metrics ($80M+ lobbying annually).
• National Association of Manufacturers (NAM): NAM is the largest US cross-sector manufacturing trade association and runs the same kind of large-scale federal lobbying, ad campaigns, and policy-research operations as PhRMA, but across all of US manufacturing — directly comparable in operational model if not vertical focus.
• American Hospital Association (AHA): The AHA is a larger Washington-based healthcare trade association representing hospitals, against whom PhRMA directly lobbies on the 340B drug discount program and drug pricing — same advocacy playbook at greater scale and with broader scope than pharma-only issues.

Direct peers

• AHIP (America's Health Insurance Plans): AHIP is the payer-side counterpart to PhRMA — the leading US health-insurer trade association with a parallel advocacy structure, opposing many of the same legislative fights (340B, PBM reform, drug pricing) but from the opposite negotiating position.
• Biotechnology Innovation Organization (BIO): BIO is the closest direct peer to PhRMA — the leading US trade association for the biotechnology industry, performing analogous lobbying, policy advocacy, and member-services functions on drug pricing, FDA regulation, and IP protection for a partially overlapping membership of innovative biopharma companies.
• AdvaMed (Advanced Medical Technology Association): AdvaMed is the device-side analog of PhRMA — a Washington-based trade association that conducts federal lobbying, CMS/FDA engagement, and legal advocacy on behalf of medical device manufacturers, with the same dues-funded, member-company governance model.
• Association for Accessible Medicines (AAM): AAM (formerly the Generic Pharmaceutical Association) is the generics-industry trade group that lobbies parallel to PhRMA on Hatch-Waxman, ANDA policy, and 340B — directly comparable in structure but operating across the negotiating table on pricing politics.

Emerging players

• Consumer Healthcare Products Association (CHPA): CHPA is the US OTC/consumer-health trade association with a similar dues-funded DC lobbying structure as PhRMA but a narrower product scope (OTC drugs, dietary supplements) — useful reference for adjacency on pharmacy and FDA-related lobbying.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/phrma
• Facebookfacebook.com/PhRMA
• LinkedInlinkedin.com/company/phrma

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaceutical Researcher and Manufacturers of America